Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions are flooding the market. From cardiology and imaging to oncology and primary care, clinicians are being asked to evaluate algorithms that promise earlier detection, better accuracy, and more efficient care. Many of these tools are technically impressive. Some are FDA-cleared. A few even come with early clinical data. Yet only a relatively small number have become part of routine clinical practice.
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Related Articles
Anumana Named to Fast Company’s 2026 Most Innovative Companies Awards
Recognition highlights Anumana’s leadership in AI-driven cardiovascular detection and clinical decision support CAMBRIDGE, Mass., March 24, 2026—Anumana, a leader in AI-powered cardiovascular detection algorithms, today announced it has been named…March 24, 2026
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early…May 23, 2022
Anumana’s ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status
Medical Product Outsourcing: Artificial intelligence (AI)-driven healthtech company, Anumana has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI-enhanced, ECG-based pulmonary hypertension (PH) early detection algorithm.…May 23, 2022
Anumana Joins the American College of Cardiology to Advance AI-Powered Solutions for Detecting Heart Failure
Anumana’s joins ACC to advance AI solutions for detecting heart failureDecember 12, 2024


